This page shows what was measured, who it was measured in, and what that does not settle.
What Chlorotrianisene does in the body
RNAWiki has not recorded what this substance changes in the body.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. It is a prescription or clinician-administered medicine where it is approved.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 6V5034L121 · read 2026-08-29
Its recorded molecular formula is C23H21ClO3, weighing 380.9.
PubChem record · 11289 · read 2026-08-29
Where each sentence above came from
No plain explanation of what this changes is stored.
No recorded use is stored in reader language.
No statement of the main limit is recorded.
The four opening statements run to 26 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Time to progression
✗ The study did not show it
Who was studied
NCT01393093
How many people
2840
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Time to progression
✗ The study did not show it
Who was studied
NCT01393197
How many people
2480
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
The response to treatment
✗ The study did not show it
Who was studied
NCT03910140
How many people
2000
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
To determine the cumulative rate of CTCAE v5.0 Grade ≥3 acute and late treatment related adverse events within 1 year of definitive reirradiation completion using proton therapy for recurrent or second primary tumor.
✗ The study did not show it
Who was studied
NCT05313191
How many people
1800
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Mean concentration of plasma AB peptides
✗ The study did not show it
Who was studied
NCT01315639
How many people
1067
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
Overall Survival(OS)
✗ The study did not show it
Who was studied
NCT01465464
How many people
888
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.15 registered measures of this kind. 3 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat, Dog. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
maximum observed plasma concentration
Meaningful
Things that change how a life goes, not only a number.
overall survival rate
overall survival
progression free survival
survival rates
disease free survival
complete remission
recurrence free survival
progress free survival
6 month progression free survival
3 year overall survival
and 5 more.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (24)
time to progression
adverse events as a measure of safety and tolerability
safety and tolerability
freedom from local progression at 6 months and 12 months
tumor response
time to tumor progression
local control
objective response rate
time to reach cmax
area under the curve
objective response rate at 6 months
maximum tolerated dose of tocilizumab
complete response
incidence of treatment emergent adverse events
tumor size
amendable to curative surgical interventions
adverse events
serious adverse events
who died
adverse events leading to study drug discontinuation
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
No description of who was studied is recorded.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Varies by country
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No form or route is recorded.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. It is a prescription or clinician-administered medicine where it is approved.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
A register records the withdrawal of an approval.
No source is stored against this line.
What is in the pack
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing is recorded about product quality.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Chlorotrianisene appears in spontaneous reports to regulators. Across the 1 most-reported reaction terms, 2 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear∅Nothing found in the sources checked
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
The exact form studied is not recorded.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine, withdrawn medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Chlorotrianisene studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How much did people take in the studies?
The sources RNAWiki checked hold nothing for this field.
Why it matters. A result belongs to an amount. Without the amount the result floats free.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
How fast does the body clear it?
The sources RNAWiki checked hold nothing for this field.
Why it matters. Without this, nothing on this page can say how long anything lasts.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Chlorotrianisene are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
6V5034L121
CAS registry number
569-57-3
PubChem compound
11289
ChEMBL
CHEMBL1200761
ChEBI
3641
WHO international nonproprietary name list entry
595
RxNorm concept
2397
EMA substance identifier
100000081870
European Chemicals Agency number
209-318-6
DrugBank
DB00269
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✗ Not passed
Every public sentence names a source
The opening statement carries no source: the record holds neither an explanation nor a recorded use.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
A register records the withdrawal of an approval.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
4 approved applications cover products containing this substance.
This order is fixed in code and does not count clicks or time on the page.
What is not here
7 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (13)
Q1
What did Chlorotrianisene's largest trial (4991 people) and its longest (13 years) measure?
4991 people in Chlorotrianisene's largest registered study, 13 years in its longest registered window, measuring survival of all randomized patients at month 24 (favorable event). Mortality by month 24 and withdrawal from the study will be considered to be unfavorable events. ClinicalTrials.gov · 2026-09-01
84 phase2, 43 phase3, 41 na, 25 na or unstated, 19 phase1, 8 phase4, 1 early phase1; NCT00003907; 2012-08. Last human test completed 2026, NCT04246177.
Interpretation These counts include studies where Chlorotrianisene was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
84
phase3
43
na
41
na or unstated
25
phase1
19
phase4
8
2 more recorded rows
early phase1
1
Last recorded human testNCT04246177
2026-03-26
recorded 2026-09-01 · last checked 2026-09-04
Q2
From mouse to human: where has Chlorotrianisene shown lifespan?
survival of all randomized patients at month 24 (favorable event). Mortality by month 24 and withdrawal from the study will be considered to be unfavorable… — the recorded outcome words.
Show the evidence
mouse
mechanism-only
rat
mechanism-only
dog
lifespan
humanNCT00936689
lifespan; survival of all randomized patients at month 24 (favorable event). Mortality by month 24 and withdrawal from the study will be considered to be unfavorable events.; 199
futility/efficacy (1), accrual/recruitment (10), funding/business (3), sponsor decision unspecified (2) and other (6): Chlorotrianisene's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Bayer Healthcare is no supplying the study drug"; 22 of 199 registered studies
Show the evidence
Trial
NCT00576056
terminated; "Bayer Healthcare is no supplying the study drug"
NCT01020812
terminated; "enrollment was too low"
NCT01259024
terminated; "inability to obtain CMS approval"
NCT01327521
withdrawn; "Accrual below target levels"
NCT01432314
withdrawn; "Another phase 2 randomized study has been started by other investigators."
NCT01480817
terminated; "Difficulty of participant enrollment."
14 further recorded trials
NCT02070419
withdrawn; "Principal Investigator left institution"
NCT02323360
terminated; "too slow enrollment"
NCT02762266
terminated; "Business decision - funding"
NCT02787954
terminated; "PI transferred to another institution and did not take this study with him."
NCT02821533
terminated; "Poor case accrual"
NCT02958163
terminated; "lack of recruitment"
NCT02997956
withdrawn; "funding issues"
NCT03608878
terminated; "The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is required to include the patients."
NCT03782831
withdrawn; "No participants enrolled"
NCT03791918
withdrawn; "No participants enrolled"
NCT04231929
withdrawn; "Study cancelled by Sponsor decision"
NCT04653389
terminated; "The treatment efficacy was not satisfactory."
NCT05171166
terminated; "Difficult to enroll participants"
NCT05592197
withdrawn; "This is a sub-study of another one."
recorded 2026-09-01 · last checked 2026-09-04
Q4
More Chlorotrianisene was worse in human: at what point?
U-shaped in human: "Pretreatment TGR is highly variable in HCC before TACE with a U-shaped distribution for the prediction of tumor response." Europe PMC · dose-response search · 2019-08-20
5 recorded sentences naming Chlorotrianisene; U-shaped, biphasic
Show the evidence
U-shapedPMID 31369166
"Pretreatment TGR is highly variable in HCC before TACE with a U-shaped distribution for the prediction of tumor response."
biphasic
PMID 29680967
"PRM was applied to biphasic CT data obtained at baseline and following 3 TACE treatments of 20 patients with HCC tumors ≥ 2 cm."
PMID 16724976
"This review describes MDCT, its biphasic scanning, its evaluation of blood supply in HCC and the subsequent classification of HCC, its therapeutic significance before TACE and the prognostic value after TACE."
PMID 12461260
"To evaluate the additional diagnostic value of unenhanced computed tomographic (CT) images in the depiction of viable tumor in patients who were treated with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) and followed up with biphasic helical CT that included the acquisition of unenhanced images."
PMID 12461260
"The study data demonstrate the diagnostic value of unenhanced images interpreted in conjunction with biphasic CT images for follow-up of patients who have previously been treated with TACE for HCC."
recorded 2019-08-20 · last checked 2026-09-04
Q5
Could one person measure Chlorotrianisene's effect on time to progression?
Time to progression: measured in Chlorotrianisene's trials.
Interpretation time to progression is the recorded endpoint.
Show the evidence
biomarkers
time to progression; 2026-09-01
overall survival rate; 2026-09-01
overall survival; 2026-09-01
progression free survival; 2026-09-01
survival rates; 2026-09-01
disease free survival; 2026-09-01
14 more recorded rows
biomarkers
adverse events as a measure of safety and tolerability; 2026-09-01
biomarkers
safety and tolerability; 2026-09-01
biomarkers
freedom from local progression at 6 months and 12 months; 2026-09-01
biomarkers
tumor response; 2026-09-01
biomarkers
time to tumor progression; 2026-09-01
biomarkers
local control; 2026-09-01
biomarkers
complete remission; 2026-09-01
biomarkers
objective response rate; 2026-09-01
biomarkers
recurrence free survival; 2026-09-01
biomarkers
maximum observed plasma concentration; 2026-09-01
biomarkers
time to reach cmax; 2026-09-01
biomarkers
area under the curve; 2026-09-01
biomarkers
progress free survival; 2026-09-01
biomarkers
6 month progression free survival; 2026-09-01
human trials at or under30
50
Not recorded for this substance
a recorded half-life
smallest human trial
0; NCT01327521; PHASE3; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q6
Which of 3 year overall survival, 6 month progression free survival and adverse events did Chlorotrianisene's trials measure?
3 year overall survival, 6 month progression free survival and adverse events lead 40 outcome terms across Chlorotrianisene's trials. ClinicalTrials.gov · 2026-09-01
progression free survival, survival rates, disease free survival, adverse events as a measure of safety and tolerability, safety and tolerability and freedom from local progression at 6 months and 12 months follow.
Show the evidence
time to progression
1
overall survival rate
1
overall survival
1
progression free survival
1
survival rates
1
disease free survival
1
14 more recorded rows
adverse events as a measure of safety and tolerability
1
safety and tolerability
1
freedom from local progression at 6 months and 12 months
1
tumor response
1
time to tumor progression
1
local control
1
complete remission
1
objective response rate
1
recurrence free survival
1
maximum observed plasma concentration
1
time to reach cmax
1
area under the curve
1
progress free survival
1
6 month progression free survival
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Chlorotrianisene's 40 ongoing trials reports first?
Overall Survival; To evaluate the 6-month progression free survival (PFS) in participants with advanced HCC BCLC stage B treated with bevacizumab, durvalumab, tremelimumab and TACE; latest 2032-08-31
Show the evidence
Trial
NCT03895359
"Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma"; n 128; "Overall Survival"; 2027-06-01
NCT03937830
"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma"; n 27; "To evaluate the 6-month progression free survival (PFS) in participants with advanced HCC BCLC stage B treated with bevacizumab, durvalumab, tremelimumab and TACE"; 2027-12-31
NCT04472767
"Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma"; n 35; "Percentage of Participants with Progression-free Survival at 6 Months"; 2027-09-01
NCT04728633
"Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases"; n 28; "Best response to treatment"; 2027-06-30
NCT04803994
"The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma"; n 434; "Time to failure of treatment strategy"; 2027-07
NCT04954781
"TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma"; n 25; "Objective Response Rate (ORR)"; 2025-07-15
14 further recorded trials
NCT04988945
"TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma"; n 33; "Downstaging for hepatectomy"; 2026-12-01
NCT04996914
"Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma"; n 30; "1-year local control rate"; 2029-05-05
NCT05171335
"Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients"; n 50; "Percent Tumor Necrosis"; 2027-12-30
NCT05319431
"A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC"; n 60; "Progression-free survival (PFS)"; 2025-06-30
NCT05320692
"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma"; n 423; "PFS assessed by BIRC"; 2026-07-30
NCT05672108
"Phase II Trial of Lung Chemoemobolization"; n 30; "Local progression free survival"; 2027-10-28
NCT05718232
"SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)"; n 136; "Overall Survival (OS)"; 2027-02
NCT05920863
"Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors"; n 35; "Major pathological response"; 2025-12-31
NCT05984511
"TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT"; n 234; "Overall survival (OS)"; 2029-08-01
NCT06261814
"Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors"; n 266; "Recurrence"; 2028-01-01
NCT06371157
"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma"; n 469; "Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)"; 2026-05-23
NCT06602986
"Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma"; n 96; "Measuring the density of Iodine in Lipiodol depositions: Detecting an Invisible Residual Tumor after Conventional Transarterial Chemoembolization for Hepatocellular carcinoma"; 2025-07-13
NCT06609850
"The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma"; n 116; "Progression free survival (PFS)"; 2028-10-30
NCT06641713
"HAIC Compared With TACE in Huge Hepatocellular Carcinoma"; n 664; "Objective response rate"; 2025-12-30
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which running trial of Chlorotrianisene could settle lifespan?
NCT05319431 measures Progression-free survival (PFS), reading out 2025-06-30.
18 open trials; n 60; "A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC"
Show the evidence
Trial
NCT05319431
"A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC"; n 60; "Progression-free survival (PFS)"; 2025-06-30
NCT06898398
"TACE Combined Surgery for the Resectable Huge HCC"; n 326; "Recurrence-free survival （RFS）"; 2025-12-30
NCT06371157
"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma"; n 469; "Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)"; 2026-05-23
NCT06740370
"TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma"; n 32; "Progression-Free-Survival (PFS)"; 2026-08-30
NCT05718232
"SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)"; n 136; "Overall Survival (OS)"; 2027-02
NCT03895359
"Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma"; n 128; "Overall Survival"; 2027-06-01
12 further recorded trials
NCT04472767
"Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma"; n 35; "Percentage of Participants with Progression-free Survival at 6 Months"; 2027-09-01
NCT05672108
"Phase II Trial of Lung Chemoemobolization"; n 30; "Local progression free survival"; 2027-10-28
NCT07209813
"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma"; n 48; "Progression-Free Survival (PFS) Assessed by Independent Review Committee Based on mRECIST"; 2027-10-31
NCT03937830
"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma"; n 27; "To evaluate the 6-month progression free survival (PFS) in participants with advanced HCC BCLC stage B treated with bevacizumab, durvalumab, tremelimumab and TACE"; 2027-12-31
NCT06896396
"Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma"; n 60; "Progression Free Survival (PFS)"; 2028-02-01
NCT07487662
"TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk"; n 105; "1-year recurrence-free survival rate"; 2028-03-17
NCT06609850
"The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma"; n 116; "Progression free survival (PFS)"; 2028-10-30
NCT07340502
"TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma"; n 364; "Progression-free survival (PFS)"; 2028-12-31
NCT06844357
"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer."; n 300; "Progression-free survival (PFS)"; 2029-04-01
NCT05984511
"TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT"; n 234; "Overall survival (OS)"; 2029-08-01
NCT07712094
"AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer"; n 56; "progression-free survival (PFS)"; 2029-08-31
NCT07309419
"A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma"; n 222; "Overall Survival (OS)"; 2030-06-30
Q9
Which 40 trials of Chlorotrianisene posted no result?
Posted no result
40 of 40 completed trials
Registrations
NCT00646100, NCT00834158, NCT00817895, NCT00825669, NCT01042041 and NCT00827554, and 34 more
Completion dates
oldest 2010-02; newest 2024-05-30
Show the evidence
Trial
NCT00646100
2010-02
NCT00834158
2010-11
NCT00817895
2010-12
NCT00825669
2010-12
NCT01042041
2010-12
NCT00827554
2011-10
14 further recorded trials
NCT00919009
2011-12
NCT00357474
2012-02
NCT00820157
2012-12
NCT00936689
2012-12
NCT00467974
2014-11
NCT01332669
2015-05
NCT02728219
2015-05
NCT02724358
2015-12
NCT02724436
2015-12
NCT02547480
2017-09-19
NCT02006030
2017-11-01
NCT01933945
2017-11-10
NCT03636620
2018-08
NCT01300143
2018-10-26
Q10
At the median, Chlorotrianisene's trials enrolled 99 people — anything larger?
Median enrolment
99
Largest enrolment
4991
Registered trials counted
198
Q11
What do 2 spontaneous reports say about Chlorotrianisene — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Chlorotrianisene appears in spontaneous reports to regulators. Across the 1 most-reported reaction term, 2 reaction mentions were counted: pancreatic neuroendocrine tumour metastatic 2. open-targets-adr · CHEMBL1200761 · 2026-06-24
Show the evidence
pancreatic neuroendocrine tumour metastatic
2
recorded 2026-06-24 · last checked 2026-09-04
Q12
Was Chlorotrianisene studied with exercise?
exercise is named in Chlorotrianisene's label sentences: "Thirty male C57BL/6J mice were randomized into sham-operated group, TAC model group, and TAC with aerobic exercise (TACE) group." openfda-label+europepmc · 2026-04-01
1 recorded statement; exercise
Show the evidence
exercise
Thirty male C57BL/6J mice were randomized into sham-operated group, TAC model group, and TAC with aerobic exercise (TACE) group.
recorded 2026-04-01 · last checked 2026-09-04
Q13
What is recorded about Chlorotrianisene and AMPK?
"These targets (sPLA2, TACE, AMPK, CCR2, P38 MAPK, VEGFR2, and ALK5) were validated by RT-qPCR, demonstrating significant regulation in lung tissues." — where Chlorotrianisene and AMPK appear together. Europe PMC · pathway abstract search · 2025-09-08
"These targets (sPLA2, TACE, AMPK, CCR2, P38 MAPK, VEGFR2, and ALK5) were validated by RT-qPCR, demonstrating significant regulation in lung tissues."
autophagyPMID 40930288
"Licorice (0.06 g/kg, 7d) emerged as a core herb, with its active component licochalcone B significantly inhibiting TACE, mediating autophagy promoting SGs disassembly and potentially clearing residual mRNA."
sirtuinPMID 38558505
"WD/CCl<sub>4</sub> mice showed increased TACE activity with reduced hepatic expression of sirtuin 1 (Sirt1) and tissue inhibitor of metalloproteinase 3 (Timp3)."
autophagy
PMID 36848495
"Herein, pH-responsive poly(acrylic acid)/calcium phosphate nanoparticles (PAA/CaP NPs) were synthesized and used as the carrier of epirubicin (EPI) to enhance the efficacy of TACE therapy through autophagy inhibition."
PMID 36848495
"This study not only develops a new delivery system for TACE but also provides a promising strategy targeting autophagy inhibition to improve the therapeutic effect of TACE for the HCC treatment."
mTOR
"We discovered Cezanne modulates EMT by activating the AKT/mTOR signaling pathway and provided evidence for the rationale of combining mTOR inhibitor with TACE to prevent recurrence in HCC patients.</p>"
sirtuin
PMID 23703665
"Because the main natural regulator of TACE activity is the tissue inhibitor of metalloproteinase 3 (Timp3), we hypothesized that AGEs induce TACE through nicotinamide adenine dinucleotide phosphate reduced oxidase 2 (NOX2); and the down-regulation of Sirtuin 1 (Sirt1)/Timp3 pathways mediate fibrogenic activity in NASH."
PMID 23703665
"In vitro, AGE exposure decreased Sirt1 and Timp3 in hepatic stellate cells by a NOX2-dependent pathway, and TACE was induced after exposure to AGEs."
mTOR
PMID 26496775
"Our study suggests that upregulation of CD147 under starvation may reduce hepatoma cell death by modulating both apoptosis and autophagy through mTOR signaling, and that CD147 may be a novel potential molecular target to improve the efficacy of TACE."
PMID 32212134
"Key Points • Recurrent HCC after OLT management is challenging and notoriously difficult. • High oncologic-risk patient identification and close follow-up are essential. • Recurrences diagnosed within the first 2 years after OLT can be classified as early-onset and are associated with poor prognosis. • Surgical resection should be the first curative attempt when it is technically feasible. • TACE…"
IGF-1PMID 20139073
"Finally, we also show that IGF-1 induces PKC-dependent phosphorylation of TACE."
recorded 2025-09-08 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 9 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.